Laura, mother of Donovan
On treatment day, we were excited, we were hopeful. We were so happy that today we are making a difference. Today we’re going to do something that’s going to help him.
What is ZOLGENSMA?
ZOLGENSMA® (onasemnogene abeparvovec-xioi) is a gene therapy approved by the US Food and Drug Administration (FDA) for children less than 2 years old with spinal muscular atrophy (SMA). ZOLGENSMA is:
- A one-time-only dose
- Given intravenously (IV)
- An infusion that takes 60 minutes